Annette M. Lim - Concepedia

Author

Annette M. Lim

Also Known As

A. Lim, A. M. L. Lim, A.M. Lim, A.M.L. Lim, Angela Lim, Annette Lim, Annette M Lim, Annette M. Lim, Annette May Ling Lim, Lim, Annette

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Royal Brisbane and Women's Hospital Sir Charles Gairdner Hospital The University of Queensland

About

Annette M. Lim is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	393
2	Health Sciences	5	5	209
3	Pathology	3	3	64
4	Immunology	2	2	36
5	Cell Biology	1	1	32

Annette M. Lim

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma Neil D. Gross, David M. Miller, Nikhil I. Khushalani, New England Journal of Medicine	2022	288
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing Danny Rischin, Michael R. Migden, Annette M. Lim, Journal for ImmunoTherapy of Cancer	2020	169
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis Danny Rischin, Nikhil I. Khushalani, Chrysalyne D. Schmults, Journal for ImmunoTherapy of Cancer Cancer ManagementMedian TimeDermatologyOncologyObjective Response Rate	2021	101
Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma Richard J. Young, Danny Rischin, Richard Fisher, Cancer Epidemiology Biomarkers & Prevention	2011	91
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study Neil D. Gross, David M. Miller, Nikhil I. Khushalani, The Lancet Oncology Surgical OncologySurvival OutcomesNeoadjuvant CemiplimabMedicineSurgery	2023	90
Differential mechanisms of <i>CDKN2A</i> (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome Annette M. Lim, Hongdo Do, Richard J. Young, International Journal of Cancer	2014	60
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial Annette M. Lim, Danny Rischin, Richard Fisher, Clinical Cancer Research	2011	52
A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma Bella Nguyen, Katie Meehan, Michelle R. Pereira, Scientific Reports	2020	49
BRAF Inhibition in<i>BRAF</i><sup>V600E</sup>-Positive Anaplastic Thyroid Carcinoma Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Journal of the National Comprehensive Cancer Network	2016	42

Page 1